Detalles de la búsqueda
1.
Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma.
Cancers (Basel)
; 15(13)2023 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37444637
Resultados
1 -
1
de 1
1
Próxima >
>>